Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk

Amaro, José Manuel; Villanego, Florentino; Naranjo, Javier; Orellana, Cristhian; Vigara, Luis Alberto; Narváez, Carlos Eduardo; Torrado, Julia; Cazorla, Juan Manuel; Rodríguez, Claudia; Mazuecos, Auxiliadora

doi:10.1016/j.nefroe.2024.01.015

Nefrología (English Edition)

2024

DOI: 10.1016/j.nefroe.2024.01.015

|View full text |Cite

Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk

José Manuel Amaro,

Florentino Villanego,

Javier Naranjo

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

PCSK9 in metabolism and diseases

Ajoolabady,

Pratico,

Mazidi

et al. 2025

Metabolism

View full text Add to dashboard Cite

PCSK9 in metabolism and diseases

Ajoolabady,

Pratico,

Mazidi

et al. 2025

Metabolism

View full text Add to dashboard Cite

A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review

Rajendran,

Nandhakumar,

Eerike

et al. 2024

Cureus

View full text Add to dashboard Cite

Newer drugs, such as bempedoic acid, inclisiran, alirocumab, and evolocumab have recently been introduced for dyslipidemia. This systematic review aims to perform a comparative analysis of these drugs' low-density lipoprotein cholesterol (LDL-C)-lowering activities. The PubMed database was utilized to search for randomized controlled trials. Articles were screened and selected based on specific inclusion and exclusion criteria. The primary outcome of this review is to compare the percentage reduction of LDL-C and apolipoprotein-B, along with the number of reported serious adverse events (SAEs) in trials specific to each drug. A total of 14 studies were included, four for bempedoic acid and alirocumab and three for evolocumab and inclisiran. The maximum percentage reduction in LDL-C and apolipoprotein-B from baseline to 12 weeks was observed with alirocumab, administered at 150 mg subcutaneously twice weekly for 12 weeks, achieving reductions of 72.4% and 57.9%, respectively. Lesser reductions were observed with bempedoic acid, administered at 180 mg once daily orally for 12 weeks. The highest number of SAEs were reported with bempedoic acid (216, 10%) and inclisiran (181, 11%; 175, 11%). This systematic review showed that alirocumab achieved the greatest reductions in LDL-C and apolipoprotein-B and a better safety profile. Newer LDL-C-lowering drugs show promise in improving lipid profiles, patient compliance, and safety. However, these findings are not conclusive, as other factors also influence treatment choice.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment with PCSK9 inhibitors in patients with chronic kidney disease at very high cardiovascular risk

Cited by 2 publications

References 7 publications

PCSK9 in metabolism and diseases

PCSK9 in metabolism and diseases

A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review

Contact Info

Product

Resources

About